RPRX
Royalty Pharma
$58.73
−$0.10 (−0.17%)Jul 27, 2026
Key metrics
The numbers that frame RPRX today
- Market cap
- $33.82B
- P/E (TTM)
- 40.9
- EV / FCF
- 18.0
- Gross margin
- 100%
- EV / Sales
- 17.3
- ROIC
- 4.5%
- Div yield
- 1.52%
- Debt / equity
- 0.9
- 52wk Low
- $33.57
- 52wk High
- $59.72
Growth
Revenue and earnings trend for RPRX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RPRX
Is Royalty Pharma a good buy?
Yes. Royalty Pharma has excellent momentum, and it outweighs the weak quality here. Growth looks strong, which supports the long-term business case. We think Royalty Pharma is selling at a fair price.
What is the market capitalization of RPRX?
Royalty Pharma's market capitalization is $33.82B.
What is the P/E ratio for RPRX stock?
Royalty Pharma's current P/E ratio is 40.9.
What is the 52-week high for RPRX stock?
The 52-week high for Royalty Pharma is $59.72. The current close of $58.73 is 1.7% below that high.
What is the 52-week low for RPRX stock?
The 52-week low for Royalty Pharma is $33.57. The current close of $58.73 is 75% above that low.
Does RPRX stock pay dividends?
Royalty Pharma pays a dividend. The latest dividend per share in the company data is $0.90, which implies a yield of 1.52% based on the current close.
What is the Debt / Equity ratio for RPRX?
Royalty Pharma's Debt / Equity ratio is 0.9.